@article { author = {Sagheb, Mohammad Mahdi and Sajjadi, Sharareh and Sajjady, Golmehr}, title = {Antitetanus Toxoid Antibody Titer of Chronic Hemodialysis Patients in Iran}, journal = {Iranian Journal of Immunology}, volume = {5}, number = {1}, pages = {45-50}, year = {2008}, publisher = {Shiraz Institute for Cancer Research}, issn = {1735-1383}, eissn = {1735-367X}, doi = {}, abstract = {Background: Patients with end stage renal disease have higher incidence of infection dis-eases that is thought to be related to impaired immune system. Objective: To determine the antitetanus IgG antibody level in Iranian hemodialysis patients with end stage renal disease and to find its association with sex, age, blood hemoglobin, serum albumin, dura-tion of dialysis, time of dialysis per week, dialysis adequacy, erythropoietin, or iron sup-plementation, body mass index (BMI) and underlying renal disorder. Methods: We con-ducted a cross sectional study on a total of 108 Iranian hemodialysis patients with end stage renal disorder, and 36 healthy individuals in the control group matched with the pa-tient group. The patients and controls did not receive any antitetanus vaccine or immu-noglobulins a year prior to the investigation. The serum antitetanus IgG antibody levels were measured by an ELISA method. Results: We found 74.3% of patients to have un-protected antitetanus IgG antibody level compared with 52.8% of the control group. Ex-cept hemodialysis duration, none of the contributing factors seemed to affect immunity. Conclusion: We conclude that in our study, there is a significant difference in the an-titetanus IgG antibody level between hemodialysis patients and the control group and also in the chronic hemodialysis patients.}, keywords = {Antitetanus IgG,hemodialysis,chronic renal failure}, url = {https://iji.sums.ac.ir/article_17099.html}, eprint = {https://iji.sums.ac.ir/article_17099_4d48b675cfa820e1963519d1b84d1f71.pdf} }